GB2425538A - Substrate and method for modulating tissue formation or deposition - Google Patents
Substrate and method for modulating tissue formation or deposition Download PDFInfo
- Publication number
- GB2425538A GB2425538A GB0608477A GB0608477A GB2425538A GB 2425538 A GB2425538 A GB 2425538A GB 0608477 A GB0608477 A GB 0608477A GB 0608477 A GB0608477 A GB 0608477A GB 2425538 A GB2425538 A GB 2425538A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pores
- substrate
- treated
- substrate according
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000758 substrate Substances 0.000 title claims description 67
- 238000000034 method Methods 0.000 title claims description 36
- 230000009772 tissue formation Effects 0.000 title claims description 15
- 230000008021 deposition Effects 0.000 title claims description 12
- 239000011148 porous material Substances 0.000 claims description 69
- 229920001169 thermoplastic Polymers 0.000 claims description 11
- 239000004416 thermosoftening plastic Substances 0.000 claims description 11
- 230000004069 differentiation Effects 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 239000000463 material Substances 0.000 description 21
- 210000002381 plasma Anatomy 0.000 description 21
- 230000021164 cell adhesion Effects 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 13
- 229920001436 collagen Polymers 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229920001903 high density polyethylene Polymers 0.000 description 10
- 239000004700 high-density polyethylene Substances 0.000 description 10
- 210000000963 osteoblast Anatomy 0.000 description 10
- 238000009832 plasma treatment Methods 0.000 description 10
- 238000005245 sintering Methods 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 239000012620 biological material Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- -1 polyethylene Polymers 0.000 description 7
- 238000004626 scanning electron microscopy Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 229920000098 polyolefin Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 230000033558 biomineral tissue development Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000003075 superhydrophobic effect Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001243 pseudopodia Anatomy 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 238000012605 2D cell culture Methods 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 229910000975 Carbon steel Inorganic materials 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229920002943 EPDM rubber Polymers 0.000 description 1
- 229920000181 Ethylene propylene rubber Polymers 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000010962 carbon steel Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000004046 cell surface extension Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- HGVPOWOAHALJHA-UHFFFAOYSA-N ethene;methyl prop-2-enoate Chemical compound C=C.COC(=O)C=C HGVPOWOAHALJHA-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229920006225 ethylene-methyl acrylate Polymers 0.000 description 1
- 239000005043 ethylene-methyl acrylate Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 150000005837 radical ions Chemical class 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Sustainable Development (AREA)
- Virology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
SUBSTRATE AND METHOD FOR MODULATING
TISSUE FORMATION OR DEPOSITION
The present invention relates to a range of novel substrates used as such or in combination with methods for controlling, modulating or regulating tissue formation or deposition and related metabolic products as well as for regenerating different types of tissues in vitro and in vivo.
Cells are cultured in laboratories using tissue culture plates for in vitro studies and for tissue engineering applications.
The tissue culture plates are generally supplemented with nutrients to enable the cells and tissues to grow. However, the surface area of a tissue culture plate provides only a limited amount of space for the biological material and it does not mimic adequately the three dimensional structure of the real biological environment. It is desirable to be able to increase the amount of biological material that can be grown without using an excessive number of tissue culture plates.
EP 1 245 670 discloses a method of growing cell cultures using a scaffold formed from an open cell polymer foam that has been surface treated by an oxidative plasma discharge.
However, it would be desirable to be able to provide for and control tissue formation or deposition.
According to a first aspect of the present invention there is provided a three dimensional substrate for controlling or modulating tissue formation or deposition, the substrate comprising: a porous material in which at least one of the surface physical and chemical properties and architecture are arranged to regulate or modulate cell proliferation andlor differentiation.
Cell differentiation is defined as the process during which young, immature (unspecialised) cells take on individual characteristics and reach their mature (specialised) form and function (www.seniormag.com).
It has not previously been possible to provide for and control tissue formation and deposition in a three dimensional substrate. The ability to control tissue formation and deposition enables increased yields to be obtained or for tissue formation to be discouraged for example for medical devices, non-fouling or incubation. Tissue growth is a controlled cell growth embedded in consolidated extra cellular matrix (ECM).
The use of a porous material provides a three dimensional structure in which the combined surface area of the pores substantially increases the available area in which biological material may be grown, significantly increasing yields and offers a biometric environment for the growing cells and tissues.
The porous material may, for example, be a porous thermoplastic material such as an organic polymer, examples of which include polyolefins such as polyethylene and propylene, or nylons, polycarbonates, poly(ether sulfores), polystyrene and mixtures thereof.
The surfaces of the pores may be configured to encourage tissue growth thereon such as by one or more of using a plasma or vapour to activate the pore surfaces, ionising the pore surfaces, making the pore surfaces hydrophyllic, providing free radicals in the pore surfaces or removing oil from the pore surfaces.
When the substrate is plasma treated, the plasma is preferably at a pressure greater than 0.05 Ton. The pressure may be greater than 0.1 Ton or between 0.05 and 0. 5 Ton or between 0.1 and 0.3 Ton.
The pore surfaces preferably have a defined roughness or rugosity. The pore surfaces preferably have an average rugosity of not lower than 45nm, more preferably not lower than 48nm to encourage cell adhesion or not higher than 45nm, more preferably not higher than 42nm to reduce cell adhesion encouraging inertness for a superhydrophobic substrate. The pore roughness may for example be caused by cracking of the surface of the pores.
The porous material preferably has pores with a diameter that is between 5 and 200 times the size of the biological material to be grown. For bacteria which are usually approximately 1 im in length, the substrate pores preferably have a mean size between 5 and 200gm in diameter, more preferably between 50 and 1 50pm and more preferably still between 75 and 125pm. For an eukaryotic cell which is typically 5-20.tm, the substrate pores preferably have a mean size greater than 20gm in diameter.
According to a second aspect of the present invention there is provided a method of controlling or modulating tissue formation or deposition, the method comprising providing a three dimensional substrate formed of porous material and arranging at least one of the surface physical and chemical properties and architecture of the porous material to regulate cell proliferation andlor differentiation.
The surfaces of the pores may for example be treated by one or more of being activated using a plasma or vapour, ionising the pore surfaces, making the pore surfaces hydrophyllic, providing free radicals in the pore surfaces or removing oil from the pore surfaces.
If the substrate is plasma treated, the plasma is preferably at a pressure greater than 0.05 Ton. The pressure may be greater than 0.1 Ton or between 0.05 and 0.5 Ton or between 0.1 and 0.3 Ton.
Once tissue has been grown on the substrate it may be used in any desired manner, such as being implanted into a body.
Embodiments of the present invention will now be described, by way of example only, with reference to the accompanying drawings, in which: Figure 1 shows a flow diagram illustrating the steps taken to prepare a porous thermoplastic substrate; Figure 2 shows a scanning electron micrograph of osteoblast cell growth in the porous thermoplastic substrate; Figure 3 compares cell growth on the porous substrate and in a tissue culture plate at different incubation times; Figure 4 compares collagen synthesis by osteoblast cells on tissue culture plates and in the porous substrate at different times after seeding; Figure 5 shows typical porosities obtained at different plasma conditions; Figure 6 shows typical surfaces with different rugosity and Figure 7 shows typical surface mineralization nuclei.
In this example the porous material is prepared by sintering thermoplastic granules, powder or pellets.
As those skilled in the art are well aware, the ability of a thermoplastic to be sintered can be determined from its melt flow index (MFI). Melt flow indices of individual thermoplastics are known or can be readily determined by methods well known to those skilled in the art. hi general, however, the MFI of a thermoplastic suitable for use in the materials and methods of the invention is from about 0 to about 15.
Suitable thermoplastics that can be used to provide the porous thermoplastic substrate include, but are not limited to, polyolefins, nylons, polycarbonates, poly(ether sulfones), polystyrene and mixtures thereof. A preferred thermoplastic is a polyolefin. Examples of suitable polyolefins include, but are not limited to: ethylene vinyl acetate; ethylene methyl acrylate; polyethylenes; polypropylenes; ethylene-propylene rubbers; ethylene- propylenediene rubbers and mixtures and derivatives thereof. A preferred polyolefin is polyethylene. Examples of suitable polyethylenes include, but are not limited to, low density polyethylene, linear low density polyethylene, high density polyethylene, ultra- high molecular weight polyethylene, and derivatives thereof.
PRE-PROCESSJNG
Thermoplastic particles are made using cryogenic or ambiently grinding and screened to ensure a proper particle size distribution. This step gives the optimum pore size for cell growth.
MOULD FILLING
The powder is placed in a mould, or multiple moulds, such that there is an adequate number of cavities to meet the volume demands of the commercial application. Moulds are produced of carbon steel, stainless steel, brass, or aluminium, and may have a single cavity, or up to several hundred. The number of cavities is also a function of the part geometry, and the heating method required to assure consistent parts. Mould filling is preferably assisted by using commercial powder handling and vibratory equipment.
SINTERING
Thermal processing is carried out by introducing heat to the mold, using any of the various controllable heating means. Electrical resistance heating, electrical induction heating, or steam heat may be used. The applied heat is controlled as appropriate to allow softening of the polymer particles and allow inter-particle binding to occur. Processing of parts with consistent porosity, strength, and flow characteristics is dependent on carefully considered application of commercial process control equipment. Control of the temperature cycle must allow consistent part manufacture such that there are no problems with under-processing which leads to weak, unsintered parts, or overprocessing, leading to glazed, non-porous parts.
Another method is available where material is laid down on a suitable belt and passed through a sintering oven to make continuous sheet which can be later fabricated into required shapes.
MOULD STRIPPING
Product is removed from the mould.
SURFACE TREATMENT
In this example the porous substrate is subject to plasma treatment using one or more suitable gases e.g. oxygen, air, nitrogen, ammonia, carbon dioxide which generates the presence of suitable radical ions on the surface of the sintered porous plastic. Suitable plasmas for use in the method of the invention include non-equilibrium plasmas such as those generated by radio frequencies (RF), microwaves or direct current (DC). They may operate at atmospheric or sub-atmospheric pressures as are known in the art.
The effect of treatment can be measured by applying droplets of liquids of different surface tensions on to the treated material and observing the absorption of the liquid over time or measuring the contact angle of differing surface tension liquids and therefore determining the surface energy.
Parameters used in determining the effect of the treatment include time, pressure, power/unit area, 02 concentration,
EXAMPLE 1
MATERIAL PREPARATION
DOW 53050E high density polyethylene pellets were ambiently ground and polished to give a particle distribution of: >600tm 2% 425-600jtm 39% 300-425gm 31% <300pm 28%
SINTERING
A im x im sheet 3.2mm thick was prepared by sintering the ground pellets using a continuous belt method at the temperature of 2 10 C and a belt speed of 1.25m/min. The sintered material had a mean flow pore size of 95pm and a porosity of5l%.
PLASMA TREATMENT
12mm diameter discs were cut from the sheet and placed randomly in the plasma chamber between the electrodes. The plasma chamber was sealed and evacuated to 0.O2torr to remove any possible volatile contaminants from the sintered plastic. A continuous flow of air was admitted into the chamber to a pressure of 0.2torr. The plasma was then ignited by applying a high frequency voltage at 13.56 M}Iz at a power of 35W, continuously for a period of 20 minutes. The chamber was returned to atmospheric pressure and the treated material removed.
De-ionised water droplets were then placed on the surface of the treated material and were absorbed into the structure immediately indicating the production of a satisfactory porous substrate.
MATERIAL ANII METHODS
Cell adhesion and bone noduli formation: Cell line human MG63 cells (10 x i05 cell/ml, ATCC catalogue No. CRL-1427) were incubated in tissue culture plates (TCP, Nunc) for 24 h in Minimum Essential Media Eagle (MEM, Sigma Cat No. M2279) enriched with 0.292g/L L-Glutamine, 1% (vlv) non essential amino acids (Sigma Cat. No. M7145) and 10% (v/v) foetal calf serum at 37 C under a 95% air, 5% CO2 flow. The medium was made osteogenic by the addition of glycerophosphate (10pm) and ascorbic acid (250pm).
Cells were allowed to proliferate for 48h, washed with calcium-free phosphate buffered saline pH 7.4 (Oxoid, UK). After incubation MG63 osteoblasts were fixed in formalin for 1 h at room temperature, washed 3 times with PBS, underwent a rapid wash in deionised water and stepwise prior to preparation for examination by scanning electron microscopy.
Electron Microscopy 12mm diameter discs incubated with osteoblast cells were fixed for 1 hour in 2.5% glutaraldehyde and then dehydrated using a series of ethanol in water solutions (25% V/s, 50% "/.,, 75% "/, and 2 changes of 100%). The dehydrated samples were freeze dried (12 hours) prior to mounting on aluminum sample stubs fitted with adhesive pads. The discs were then sputter coated with palladium using a voltage of 2.2 kv. The cell bearing supports were imaged using a JEOL 6310 scanning electron microscope at an accelerating voltage of 5kv.
Collagen and protein synthesis. The synthesis of collagen produced by the MG63 osteoblasts was evaluated at different incubation times (24, 48, and 72h). The cells adhering on the tested substrates were trypsinised by a standard procedure, lysated by the addition on 01% (w/v) Triton, and centrifuged for 5 mm at 500x g and the supernatants (50.tl) tested for their collagen content by quantative Sirius Red method. A standard curve was obtained using collagen type I (Sigma, UK, catalogue No. C9879) in the concentration range 5gg/50p.1 to 20gI50pJ. The total protein content of each sample was evaluated by a Bradford's microplate assay (Biorad, UK, catalogue No. 500-0006).
Collagen data were expressed as collagen tg/g of protein mean standard deviation from n = 6. Protein data were expressed as protein jig/mi mean / standard deviation from n =6.
Alkaline phosphate (ALP) activity. Cells (1 05/mI) were incubated for 24 h, detached from the substrate by trypsin and lysated. The samples were centrifuged and the supematants stored at -70 C until use. An ALP microplate assay was performed as described elsewhere. Briefly, S0jil of each sample were added to 5Opi of 100 mM p- nitrophenoiphosphate (Sigma UK) and incubated for 30 mm at 37 C. The reaction was stopped by adding 5OpJ of 1M NaOH. The absorbance was read by a Titertek Multiscan Pluse microplate reader (ICN Flow, UK) at 405nm. The total protein content was also estimated by a Biorad microplate protein assay based on the Bradford's method (catalogue n. 500-0201). Data were expressed either as ALP activity (Sigma mU/ml) or as ALP specific activity (Sigma mU/jig of protein) mean standard deviation from n=6.
RESULTS
Figure 2 shows osteoblast cells growing over the surface of the polymer matrix (1) and forming tissue (2). The osteoblasts were seen to adhere and proliferate on the surface of the candidate substrate as shown in Figure 2. In particular the cells formed typical bone noduli which were not observed on tissue culture plastic. Unlike the tissue culture plate, these noduli were encouraged to develop into a 3-D space by the porous architecture of the substrate.
CELL DIFFERENTIATION
Figure 3 shows ALP activity of the cells on the porous substrate and TCP at different incubation times. Osteoblast differentiation on the candidate discs was evaluated as a measure of the alkaline phosphatase activity produced by the cells during their contact with the materials for 24hours (h), 48hours (h) and 72hours (h) and compared with their differentiation on conventional tissue culture plates (TCP). Data were normalised as ALP mU/pg of proteins. Although, a similar ALP activity peak at 48h was observed for both the substrate types, osteoblasts have a significantly higher degree of differentiation on porous scaffolds. Figure 3 clearly shows that the ALP activity was higher when the cells were incubated on the porous substrates.
Collagen Synthesis Figure 4 shows collagen synthesis by osteoblast cells on tissue culture plastic and candidate discs 24, 48 and 72 hours following seeding. Collagen synthesis by the osteoblasts on the porous substrate was shown to be significantly higher at 24 and not significantly different at longer incubation times as shown in Figure 4. These data combined with the cell adhesion and tissue formation studies suggest that this early production of collagen together with the porous nature of the material encourage the formation of 3-D bone noduli.
EXAMPLE 2
MATERIAL PREPARATION
DOW 53050E density polyethylene pellets were anibiently ground and polished to give a particle distribution of: >600jtm 2% 425-600jim 95% <425gm 3%
SINTERING
A im x im sheet 3.2mm thick was prepared by sintering the ground pellets using a continuous belt method at the temperature of 210 C and a belt speed of 1.25mlmin. The sintered material had a mean flow pore size of 1 50j.tm and a porosity of 51%.
PLASMA TREATMENT
12mm diameter discs were cut from the sheet and placed randomly in the plasma chamber between the electrodes. The plasma chamber was sealed and evacuated to 0.O2torr to remove any possible volatile contaminated from the sintered plastic. A continuous flow of air was admitted into the chamber to a pressure of 0.2torr. The plasma was then ignited by applying a high frequency voltage 13.56 MHz at a power of 35W, continuously for a period of 20 minutes. The chamber was returned to atmospheric pressure and the treated material removed.
De-ionised water droplets when placed on the surface of the treated material were absorbed into the structure immediately indicating the provision of a satisfactory porous substrate.
EXAMPLE 3
MATERIAL PREPARATION
DOW 53050E high density polyethylene pellets were ambiently ground and polished to give a particle distribution of: >425 4% 300-425 93% <300 3%
SINTERING
A im x im sheet 3.2nmi thick was prepared by sintering the ground pellets using a continuous belt method at the temperature of 210 C and a belt speed of 1.25mlmin. The sintered material had a mean flow pore size of 60 jtm and a porosity of 46%.
PLASMA TREATMENT
12mm diameter discs were cut from the sheet and placed randomly in the plasma chamber between the electrodes. The plasma chamber was sealed and evacuated to 0.O2torr to remove any possible volatile contaminated from the sintered plastic. A continuous flow of air was admitted into the chamber to a pressure of 0.2torr. The plasma was then ignited by applying a high frequency voltage at 13.56 MHz at a power of 35W, continuously for a period of 20 minutes. The chamber was returned to atmospheric pressure and the treated material removed.
De-ionised water droplets when placed on the surface of the treated material were absorbed into the structure immediately indicating the provision of a satisfactory porous substrate.
The attached Table - Appendix 1 - indicates the results achieved for porous three dimensional substrates prepared with a variety of properties indicated in the table, for example pore size, various pressures and times of plasma treatment and mgosity of the pore surfaces.
The different plasma treatment conditions offer a series of materials which support cell adhesion and differentiation at different degrees or are able to prevent cell adhesion (SuperHydrophobic), where cell differentiation is defined as: "the process during which young, immature (unspecialised) cells take on individual characteristics and reach their mature (specialised) form and function (www.seniormag.com). According to this definition, plasma- treated three dimensional (3D) scaffolds supporting cell adhesion and differentiation offer the additional benefit of inducing the formation of tissue noduli and the deposition of a more consolidated, mineralized extracellular matrix. Indeed, the almost inverse relationship between concentrations of soluble collagen and levels of deposited ECM indicates that a tissue more stable than traditional 2D substrates is formed on the 3D scaffolds. Tissue noduli were obtained in traditional 2D cell culture conditions in 72 hours (h). SuperHydrophobic scaffolds are relatively inert towards cell adhesion (limited to the first 24 h only) and they are particularly suitable for testing cell adhesion properties of deposited coatings (e.g. biomaterials for biomedical applications) or grafted molecules (e.g. structural proteins) in a 3D environment. They can also be used as biomaterials for biomedical implants capable of supporting biomaterials or bioactive molecules with cell adhesion properties. The deposition of a stable coating of these specific cell substrates is ensured by the relatively high hydrophobicity of the treated 3D scaffold. The different degrees of cell adhesion which can be achieved on these scaffolds also widen the range of substrates available to test drugs in clinically-reflective conditions in vitro.
As can be seen from the table of Appendix 1, different conditions encourage or reduce cell adhesion. For example, if the plasma treatment occurs at a pressure greater than 0.05 Torr or greater than 0.1 Torr cell adhesion is increased. By way of a further example, if the rugosity is not lower than 45nm cell adhesion occurs whereas if the rugosity is not higher than 45nm cell adhesion is reduced.
Figures 5, 6 and 7 show graphically some of the results of Appendix 1. Figure 5 shows typical porosities obtained at different plasma conditions. Macroporosity was always greater than 300 jim as shown in Appendix 1. Some samples of Appendix 1 exhibited the formation of nanoporosity as shown in Figure 5C. These samples are denoted by a double asterix next to the porosity values. Figure 6 shows typical surfaces with different rugosity. Figure 6A shows an untreated surface, Figure 6B shows a superhydrophobic surface and Figure 6C shows a hydrophilic surface. The formation of nanopores is also shown in Figure 6C as indicated in Appendix 1. Figure 7 shows typical surface mineralization nuclei (brownlred precipitates). Figure 7A shows an example of a tissue culture plate (TCP) and Figure 7B shows an example of a 3D porous scaffold.
Many variations may be made to the examples, described above whilst still falling within the scope of the invention. For example instead of or as well as being subjected to plasma treatment, the pore surfaces may be treated in any suitable manner to encourage the growth of organic materials, such as one or more of ionising the pore surfaces, making the pore surfaces hydrophyllic, providing free radicals in the pore surfaces, removing oil from the pore surfaces or roughening the pore surfaces for example.
Appendix 1 Cell support properties of plasma-treated scaffolds ________________ ________________ ________________ ________________ Cell Features 2D substrate Untreated Super Hydrophilic Hydrophilic Hydrophobic treatment treatment ID RDM/1 1/175/2 RDM/1 1/175/3 RDM/1 1/175/4 RDM/1 1/175/5 Porvair Grade ____________ ____________ Vyon HP Vyon HP Vyon HP Vyon HP Material ___________ ___________ HDPE HDPE HDPE HDPE Pore Size' Max ___________ >300 >300 >300** >300** ____________________ Mean _____________ 90 90 90 90 ____________________ MIFP _____________ 25 25 25 25 Plasma Treatment Power / Watts - 40 40 40 ____________________ Time / mins _____________ - 20 20 20 __________________ Gas ____________ - PFEA Air Oxygen _____________________ Pressure / ton ______________ - 0.05 0.2 0.2 Rugosit(nm) _____________ none 63.23 8.69 36.39 9.22 51.56 5.41 48. 15 6.5 Protein synthesis - 120t 95* 92* lOlt (TCP%_at 24 h) ____________ ____________ _____________ _____________ _____________ _____________ Soluble Collagen - 120t 67* 73* 98* (TCP% at 24 h) ____________ ____________ _____________ _____________ _____________ _____________ ALP activity - 92* 91* 87* 96* (TCP% at 24 h) ____________ ____________ _____________ _____________ _____________ _____________ Cell-cell interactions Limited to cell tissue noduli apoptotic cell tissue noduli tissue noduli (SEM analysis at 72 h) ______________ lamellipodia _______________ aggregates _______________ _______________ Deposited ECM + ++ - ++++ ++++ (SEM analysis at 72 h) ______________ _____________ _______________ _______________ _______________ _______________ Tissue formation 2D 3D confluent none 2D confluent 3D confluent (SEM analysis at 72 h) _____________ Semi confluent ______________ ______________ ______________ ______________ Mineralization _____________ + -i--i-+ - + ++ Cell Features Hydrophilic Hydrophilic Hydrophilic treatment treatment treatment RDMI12/93/1 RDM/12/93/2 RDM112193/4 Porvair Grade ____________ Vyon HP Vyon HP Vyon HP Material __________ HDPE HDPE HDPE Pore Size' Max >300 >300** >300** ____________________ Mean 90 90 90 ___________________ MFP 25 25 25 Plasma Treatment Power / Watts 40 40 40 ____________________ Time / mins 20 20 60 ___________________ Gas Allylamine Air Air _________________ Pressure/ton 0.2 0.4 0.2 Rugosity ____________ 51.03 6.13 52.20 7.34 49.55 6.33 Protein synthesis 98.5t 106.6t 101.2t (TCP% at 24 h) ____________ _____________ _____________ _____________ Soluble Collagen 103t 104.4t 103.3t (TCP% at 24 h) ____________ _____________ _____________ _____________ ALP activity 98t 112t 129.6* (TCP% at 24 h) ____________ _____________ _____________ _____________ Cell-cell interactions Tissue noduli Tissue noduli Tissue noduli (SEM analysis at 72 h) _____________ ______________ ______________ ______________ Deposited ECM ++++ ++++ ++++ (SEM analysis at 72 h) _____________ ______________ ______________ ______________ Tissue formation 2D confluent 2D confluent 2D confluent (SEM analysis at 72 h) _____________ ______________ ______________ ______________ Mineralization _____________ +++ + + 1 Determined using Xonic Pormeter 3G, Xonics Corporation, Sunrise, Florida, USA 2 PFEA - 2-(Perfluorodecyl)ethyl acrylate 3. Rugosity definition: the quality or state of being rough, wrinkled, creased (www.thefreedictionary.com, http://dict.die.net). Typical graphical examples of surfaces with different rugosity are reported in Figure 5.
= value not significantly different from control tissue plate = value significantly different from 2D substrate at p<O.O5 **rrindicate the formation of nanoporosity as shown in Figure 5 C 2D= Two dimensional arrangement 2D substrate= commercial tissue culture plate 3D= Tn-dimensional arrangement Tissue noduli= cell clustering into a early tissue architecture Cell lamellipodia= cell membrane extensions driving cell/substrate and cell/cell adhesion ECM= extracellular matrix Apoptotic cell aggregates= cells which are not able to adhere onto the substrate and try to form aggregates among themselves, but soon entering a programmed cell death cycle.
Claims (38)
1. A three dimensional substrate for controlling or modulating tissue formation or deposition, the substrate comprising: a porous material in which at least one of the surface physical and chemical properties and architecture are arranged to regulate or modulate cell proliferation andlor differentiation.
2. A substrate according to claim 1, wherein the porous material is a porous thermoplastic.
3. A substrate according to claim 2, wherein the porous material is an organic polymer.
4. A substrate according to any one of the preceding claims, wherein the surfaces of the pores are activated by a plasma.
5. A substrate according to any one of the preceding claims, wherein the surfaces of the pores are activated by a vapour.
6. A substrate according to claim 4 or claim 5, wherein the substrate is plasma or vapour treated at a pressure greater than 0.05 Ton.
7. A substrate according to claim 4 or claim 5, wherein the substrate is plasma or vapour treated at a pressure greater than 0.1 Ton.
8. A substrate according to claim 4 or claim 5, wherein the substrate is plasma or vapour treated at a pressure between 0.05 Ton and 0.5 Ton.
9. A substrate according to claim 4 or claim 5, wherein the substrate is plasma or vapour treated at a pressure between 0.1 and 0.3 Ton.
10. A substrate according to any one of the preceding claims, wherein the surfaces of the pores are ionised.
11. A substrate according to any one of the preceding claims, wherein the surfaces of the pores are hydrophyllic.
12. A substrate according to any one of the preceding claims, wherein the surfaces of the pores contain free radicals.
13. A substrate according to any one of the preceding claims, wherein the surfaces of the pores are substantially oil free.
14. A substrate according to any one of the preceding claims, wherein the surfaces of the pores have a defined roughness.
15. A substrate according to any one of the preceding claims, wherein the surfaces of the pores have cracks therein.
16. A substrate according to claim 14 or claim 15, wherein the surfaces of the pores have a minimum average rugosity of 45nm.
17. A substrate according to claim 14 or claim 15, wherein the surfaces of the pores have a maximum average rugosity of 45nm.
18. A substrate according to any one of the preceding claims, wherein the pores have an average diameter that is between 5 and 200 times the size of the organic elements to be grown.
19. A substrate according to any one of the preceding claims, wherein the pores have a mean diameter of between 5 and 200J.Lm.
20. A substrate according to any one of the preceding claims, wherein the pores have a mean diameter of between 50 and 150 jtm.
21. A substrate according to any one of the preceding claims, wherein the pores have a mean diameter of between 75 and l25m.
22. A method of controlling or modulating tissue formation or deposition, the method comprising providing a three-dimensional substrate formed of porous material and arranging at least one of the surface physical and chemical properties and architecture of the porous material to regulate cell proliferation andlor differentiation
23. A method according to claim 22, wherein the surfaces of the pores are treated by being activated by a plasma.
24. A method according to claim 22 or claim 23, wherein the surfaces of the pores are treated by being activated by a vapour.
25. A method according to claim 23 or claim 24, wherein the surfaces are plasma or vapour treated at a pressure greater than 0.05 Ton.
26. A method according to claim 23 or claim 24, wherein the surfaces are plasma or vapour treated at a pressure greater than 0.1 Ton.
27. A method according to claim 23 or claim 24, wherein the surfaces are plasma or vapour treated at a pressure between 0.05 Ton and 0.5 Ton.
28. A method according to claim 23 or claim 24, wherein the surfaces are plasma or vapour treated at a pressure between 0.1 and 0.3 Ton.
29. A method according to any one of claims 22 to 28, wherein the surfaces of the pores are treated by being ionised.
30. A method according to any one of claims 22 to 29, wherein the surfaces of the pores are treated to become hydrophyllic.
31. A method according to any one of claims 22 to 30, wherein the surfaces of the pores are treated to provide free radicals therein.
32. A method according to any one of claims 22 to 31, wherein the surfaces of the pores are treated to have oil removed therefrom.
33. A method according to any one of claims 22 to 32, wherein the surfaces of the pores are treated by being roughened.
34. A method according to any one of claims 22 to 32, wherein the surfaces of the pores are treated by having cracks introduced therein.
35. A method according to claim 33 or claim 34, wherein the surfaces of the pores are treated to produce a minimum average rugosity of 45nm.
36. A method according to claim 33 or claim 34, wherein the surfaces of the pores are treated to produce a maximum average rugosity of 45nm.
37. A substrate substantially as hereinbefore described with reference to the accompanying drawings.
38. A method of controlling or modulating tissue formation substantially as hereinbefore described with reference to the accompanying drawings.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0508815.8A GB0508815D0 (en) | 2005-04-29 | 2005-04-29 | Substrate and method for growing biological material |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0608477D0 GB0608477D0 (en) | 2006-06-07 |
GB2425538A true GB2425538A (en) | 2006-11-01 |
Family
ID=34674125
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0508815.8A Ceased GB0508815D0 (en) | 2005-04-29 | 2005-04-29 | Substrate and method for growing biological material |
GB0608477A Withdrawn GB2425538A (en) | 2005-04-29 | 2006-04-28 | Substrate and method for modulating tissue formation or deposition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0508815.8A Ceased GB0508815D0 (en) | 2005-04-29 | 2005-04-29 | Substrate and method for growing biological material |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB0508815D0 (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63198980A (en) * | 1987-02-13 | 1988-08-17 | Sumitomo Electric Ind Ltd | Base material for cultivating cell |
JPS63283576A (en) * | 1987-05-15 | 1988-11-21 | Sumitomo Electric Ind Ltd | Substrate for cell culture |
US4919659A (en) * | 1985-12-16 | 1990-04-24 | The Board Of Regents For The University Of Washington | Radio frequency plasma deposited polymers that enhance cell growth |
EP0416586A1 (en) * | 1989-09-08 | 1991-03-13 | Millipore Corporation | Porous membrane having hydrophilic and cell growth promotions surface and process |
JPH03292884A (en) * | 1990-04-12 | 1991-12-24 | Mitsubishi Rayon Co Ltd | Cell cultivation |
WO1995031157A1 (en) * | 1994-05-13 | 1995-11-23 | Thm Biomedical, Inc. | Device and methods for in vivo culturing of diverse tissue cells |
WO1998021312A1 (en) * | 1996-11-08 | 1998-05-22 | Rpms Technology Limited | Human hepatocytes in three-dimensional support systems |
US5939314A (en) * | 1989-10-31 | 1999-08-17 | The United States Of America As Represented The Administrator Of The National Aeronautics And Space Administration | Distributed pore chemistry in porous organic polymers in tissue culture flasks |
WO2000034454A2 (en) * | 1998-12-05 | 2000-06-15 | Newcastle University Ventures Limited | Microcellular polymers as cell growth media and novel polymers |
WO2004060426A1 (en) * | 2002-12-30 | 2004-07-22 | Boston Scientific Limited | Engineered scaffolds for promoting growth of cells |
JP2005253305A (en) * | 2004-03-09 | 2005-09-22 | Masataka Murahara | Method for preparing three-dimensional cell culture element |
-
2005
- 2005-04-29 GB GBGB0508815.8A patent/GB0508815D0/en not_active Ceased
-
2006
- 2006-04-28 GB GB0608477A patent/GB2425538A/en not_active Withdrawn
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4919659A (en) * | 1985-12-16 | 1990-04-24 | The Board Of Regents For The University Of Washington | Radio frequency plasma deposited polymers that enhance cell growth |
JPS63198980A (en) * | 1987-02-13 | 1988-08-17 | Sumitomo Electric Ind Ltd | Base material for cultivating cell |
JPS63283576A (en) * | 1987-05-15 | 1988-11-21 | Sumitomo Electric Ind Ltd | Substrate for cell culture |
EP0416586A1 (en) * | 1989-09-08 | 1991-03-13 | Millipore Corporation | Porous membrane having hydrophilic and cell growth promotions surface and process |
US5939314A (en) * | 1989-10-31 | 1999-08-17 | The United States Of America As Represented The Administrator Of The National Aeronautics And Space Administration | Distributed pore chemistry in porous organic polymers in tissue culture flasks |
JPH03292884A (en) * | 1990-04-12 | 1991-12-24 | Mitsubishi Rayon Co Ltd | Cell cultivation |
WO1995031157A1 (en) * | 1994-05-13 | 1995-11-23 | Thm Biomedical, Inc. | Device and methods for in vivo culturing of diverse tissue cells |
WO1998021312A1 (en) * | 1996-11-08 | 1998-05-22 | Rpms Technology Limited | Human hepatocytes in three-dimensional support systems |
WO2000034454A2 (en) * | 1998-12-05 | 2000-06-15 | Newcastle University Ventures Limited | Microcellular polymers as cell growth media and novel polymers |
WO2004060426A1 (en) * | 2002-12-30 | 2004-07-22 | Boston Scientific Limited | Engineered scaffolds for promoting growth of cells |
JP2005253305A (en) * | 2004-03-09 | 2005-09-22 | Masataka Murahara | Method for preparing three-dimensional cell culture element |
Also Published As
Publication number | Publication date |
---|---|
GB0508815D0 (en) | 2005-06-08 |
GB0608477D0 (en) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | Interaction of fibroblasts on polycarbonate membrane surfaces with different micropore sizes and hydrophilicity | |
Wei et al. | Influence of surface wettability on competitive protein adsorption and initial attachment of osteoblasts | |
Yang et al. | Improving cell affinity of poly (D, L‐lactide) film modified by anhydrous ammonia plasma treatment | |
Hayman et al. | Enhanced neurite outgrowth by human neurons grown on solid three-dimensional scaffolds | |
Khorasani et al. | Plasma surface modification of poly (l-lactic acid) and poly (lactic-co-glycolic acid) films for improvement of nerve cells adhesion | |
Lee et al. | The effect of fluid shear stress on endothelial cell adhesiveness to polymer surfaces with wettability gradient | |
Novotna et al. | Tailoring of PEEK bioactivity for improved cell interaction: plasma treatment in action | |
Sultana et al. | PHBV/PLLA-based composite scaffolds fabricated using an emulsion freezing/freeze-drying technique for bone tissue engineering: surface modification and in vitro biological evaluation | |
Sousa et al. | PCL scaffolds with collagen bioactivator for applications in tissue engineering | |
Hsiue et al. | Surface characterization and biological properties study of silicone rubber membrane grafted with phospholipid as biomaterial via plasma induced graft copolymerization | |
Slepička et al. | Poly-l-lactic acid modified by etching and grafting with gold nanoparticles | |
Tajima et al. | Differential regulation of endothelial cell adhesion, spreading, and cytoskeleton on low‐density polyethylene by nanotopography and surface chemistry modification induced by argon plasma treatment | |
KR20220004613A (en) | Culture medium and uses thereof | |
Jung et al. | Biocompatibility of plasma polymerized sandblasted large grit and acid titanium surface | |
Golda-Cepa et al. | Development of crystalline–amorphous parylene C structure in micro-and nano-range towards enhanced biocompatibility: the importance of oxygen plasma treatment time | |
JP2009017809A (en) | Substrate for cell culture, method for producing the same, and method for culturing cell | |
Kurniawati et al. | Toxicity and biocompatibility profile of 3D bone scaffold developed by Universitas Indonesia: A preliminary study | |
Zhu et al. | Engineering porous polyurethane scaffolds by photografting polymerization of methacrylic acid for improved endothelial cell compatibility | |
US20180201898A1 (en) | Substrate for supporting cells and method for producing same | |
Lombello et al. | Adhesion and morphology of fibroblastic cells cultured on different polymeric biomaterials | |
GB2425538A (en) | Substrate and method for modulating tissue formation or deposition | |
Venault et al. | Spray-coating of a hydrophobic poly (tetrafluoroethylene) membrane with a copolymer containing sulfobetaine methacrylamide to boost hydration and reduce biofouling in view of improving diabetic wound management and alleviate the immune response | |
Fadeeva et al. | The hydrophobic properties of femtosecond laser fabricated spike structures and their effects on cell proliferation | |
Rusen et al. | Smart thermoresponsive surfaces based on pNIPAm coatings and laser method for biological applications | |
Nebe et al. | Osteoblast behavior in vitro in porous calcium phosphate composite scaffolds, surface activated with a cell adhesive plasma polymer layer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |